Results 51 to 60 of about 735,101 (274)

Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status

Case Reports in Oncology, 2019
Small-cell lung cancer (SCLC) is highly sensitive to platinum-based chemotherapy. However, its indication in patients with a poor performance status (PS) at initial diagnosis is controversial.
Yuka Aida, Kensuke Nakazawa, Toshihiro Shiozawa, Ryoko Ogawa, Takumi Kiwamoto, Yuko Morishima, Toru Sakamoto, Ikuo Sekine, Nobuyuki Hizawa   +8 more
doaj   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer

, 2011
Elderly and poor performance status advanced non-small cell lung cancer ( NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations.
LIN, CHIA-CHI;YANG, CHIH-HSIN, 林家齊;楊志新   +1 more
core   +1 more source

Serum Myonectin Levels Are Positively Associated With Physical Function and Lower Frailty‐Related Limitation in Maintenance Hemodialysis Patients: A Cross‐Sectional Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Maintenance hemodialysis (MHD) patients frequently suffer from frailty, characterized by reduced physical function and poor prognosis. Myokines, such as myonectin, secreted by muscle, are emerging regulators of systemic health. This study investigated the relationship between serum myonectin, adipokines (adiponectin, omentin), and ...
Kenichi Kono, Yoshifumi Moriyama, Koji Ohashi, Naoya Otaka, Minako Tatsumi, Toyoaki Murohara, Noriyuki Ouchi, Satoru Oshima   +7 more
wiley   +1 more source

Poor performance status, urban residence and female sex predict inferior survival in pediatric advanced stage mature B-NHL in an Indian tertiary care center

, 2018
Background: Advanced stage is a known prognostic factor in B-Non-Hodgkin Lymphoma (NHL); however, factors within advanced stage and overall data on pediatric B-NHL from India are lacking.
Sameer Bakhshi, Patel, Manali, Patel, Amol, Saumyaranjan Mallick, Mallick, Saumyaranjan, Bakhshi, Sameer, Meher Chand Sharma, Sharma, Meher Chand, Manali Patel, Amol Patel   +9 more
core   +1 more source

Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival [PDF]

, 2017
Introduction: 25% of patients with lung cancer have performance status 3 or 4. A pragmatic approach to investigative procedures is often adopted based on the risks and benefits in these patients and whether tissue diagnosis is necessary for ...
McCowan, Colin, Farley, John M.B., Maclay, John D., Tweed, Conor, Milroy, Robert   +4 more
core   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden [PDF]

, 2020
Background: Few real-world series on the efficacy and safety of anti-programmed cell death protein-1(PD-1)/programmed death ligand-1(PD-L1)–based therapy are available in molecularly unselected patients with poor performance status (PS) and specific ...
Fuca G., Loupakis F, de Braud F, Fassan M., Raimondi A, Lonardi S, Pietrantonio F, Randon G, Di Bartolomeo M., Marra A, Corallo S., Corti F., Belli C, de Braud F., Bocconi A, Marra A., Morano F., Salati M, Belli C., Curigliano G, Spallanzani A., Trapani D., Maddalena G, Spallanzani A, Fassan M, Randon G., Pietrantonio F., Guarini V, Loupakis F., Depetris I, Pagani F, Prisciandaro M., Di Bartolomeo M, Maddalena G., Corti F, Lonardi S., Curigliano G., Prisciandaro M, Bocconi A., Salati M., Trapani D, Raimondi A., Pagani F., Morano F, Guarini V., Corallo S, Depetris I., Fucà G   +47 more
core   +1 more source

Spatiotemporal and quantitative analyses of phosphoinositides – fluorescent probe—and mass spectrometry‐based approaches

FEBS Letters, EarlyView.
Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho, Shin Morioka, Junko Sasaki, Takehiko Sasaki   +3 more
wiley   +1 more source

Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer

, 2017
Literature on the management of nonmetastatic pancreatic ductal adenocarcinoma in patients who are elderly or have poor performance status is sparse.
Joseph M. Herman, Lauren M. Rosati
core   +1 more source

Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status. [PDF]

, 2022
Background Immune checkpoint inhibitor-based combination therapy (ICI-based combination) is a new standard of care for metastatic clear cell renal cell carcinoma (mRCC) in the frontline setting.
Romero Ferreiro, María Carmen, Carril-Ajuria, Lucía, Albiges, Laurence   +2 more
core   +1 more source